Waystar Third Quarter 2026 Earnings Conference Call - WAYSTAR HOLDING CORP

Financial Performance:

• Q3 2026 revenue reached $326 million, up 21% YoY, with 10% organic growth; Q4 revenue guidance implies ~6% growth.
• Adjusted EBITDA was $139 million (24% YoY growth) with a margin of 43%; full-year Adjusted EBITDA guidance raised to $543–$549 million.
• Unlevered free cash flow generated $115 million in Q3; operating cash flow was $104 million with CapEx at $10 million.
• GAAP net income was $31 million ($0.16/share); non-GAAP net income was $87.1 million ($0.44/share).
• Net revenue retention remained healthy at 108%, supported by a gross retention rate of 97%.
• Balance sheet strength: $277 million in cash and short-term investments; net leverage ratio decreased to 2.2x.
• Large client cohort (>$100k LTM revenue) grew to 1,488 clients (up 14% YoY), now representing ~75% of total revenue.
• Full-year revenue guidance set at $1.277–$1.287 billion (midpoint $1.282 billion), implying normalized organic growth of ~11%.

Guidance and Future Outlook:

• Q4 2026 revenue expected at ~$323 million; growth constrained by ~4 percentage points due to specific headwinds.
• Headwinds include: accelerated shift from print to digital statements, delayed revenue recognition for Iodine's performance-based anomaly detection, and unfavorable Q3/Q4 comp of three large prior-year implementations.
• Normalized Q4 organic growth rate estimated at ~10% excluding these specific timing/mix factors.
• Management expects a cleaner year-over-year comparison in 2027 as 2026 comp dynamics roll off.
• Long-term target remains low double-digit organic revenue growth and Adjusted EBITDA margins of 40% or greater.
• Iodine integration is expected to be accretive to 2027 results, driven by strong bookings exceeding plans by 74% YTD.
• Capital expenditure guidance for FY 2026 remains $55–$60 million.

Business Segments and Product Lines:

• Subscription Revenue: $181 million, up 34% YoY (12% organic); driven by core Waystar business.
• Volume-Based Revenue: $143 million, up 8% YoY, reflecting improved trends from Q2.
• Provider Revenue: $243 million, up 28% YoY (11% organic).
• Patient Payments: $82 million, up 5% YoY; growth impacted by the transition to digital statement delivery.
• Iodine Integration: Combined CDI and pre-bill anomaly detection generated <del>$30 million YTD bookings (</del>$15 million in Q3); pipeline exceeds $100 million.
• AI & Altitude: AI-powered offerings accounted for ~43% of Q3 bookings; >130 clients in early access for conversational AI.
• Product Roadmap: Launch of autonomous claim resubmission capability (estimated $5B impact annually); 20+ new AI capabilities planned; expansion of pre-bill anomaly detection into quality workflows.
• Channel Partners: Expanded partnership with a leading physical therapy system, reaching ~4,000 providers and 17M annual claims.

Market and Competitive Landscape:

• Secured the largest client win in company history: a major East Coast health system (~$7B net patient revenue) replacing >20 vendors with Waystar's full platform.
• Competitive wins include displacing incumbents via cross-sell (e.g., Texas health system replacing 2 vendors).
• Market view: Outsourcing represents 15–20% of the market; AI is expected to expand the total addressable market by displacing in-sourced labor.
• Network Scale: 8.5 billion annual transactions ($3T gross claims); 1.5 million providers connected; ~1/3 of US hospital discharges covered by clinical intelligence.
• Payer Connectivity: Added >100 direct connections in 2026, supporting nearly 50M annual transactions.
• Strategic Shift: Moving from single-point solutions to comprehensive, connected revenue cycle platforms.

Risks and Challenges:

• Revenue Timing: Larger, broader platform implementations have longer revenue conversion periods (12–18 months), causing a disconnect between strong bookings and near-term recognized revenue.
• Product Mix Shift: Transition to digital patient statements impacts near-term volume; Iodine's shift to performance-based pricing delays revenue recognition compared to previous subscription models.
• Execution Risk: Longer implementation ramp times for strategic deals may suppress near-term growth rates despite high booking momentum.
• Market Volatility: Seasonal low patient payment volumes in Q4 due to deductible resets.

Management Commentary and Tone:

• Tone remains highly confident in the underlying business fundamentals despite near-term revenue normalization.
• Management emphasizes the "autonomous revenue cycle" vision, leveraging AI agents to execute complex workflows.
• Introduction of Amit Khanna as new Chief Product and Technology Officer to accelerate AI innovation.
• CFO highlights strong capital allocation discipline, prioritizing debt reduction, organic investment in AI, and share repurchases ($21M in Q3).
• Confidence expressed that Q4 headwinds are timing/mix related rather than indicative of demand softness.

Analyst Questions and Answers:

• Bookings vs. Revenue Disconnect: Management attributes the gap to larger deal sizes and longer implementation ramps; confirms strong demand with no change in win rates.
• Iodine Pricing Model: Pre-bill anomaly detection is now priced on an outcomes/performance basis rather than subscription; this creates a longer revenue recognition cycle but strong pipeline visibility ($100M).
• 2027 Growth Outlook: Management plans to provide formal 2027 guidance next quarter; expects 2027 to be clearer with fewer comp headwinds and Iodine accretion.
• Margin Sustainability: Q4 EBITDA margin dip to ~42% is driven by product mix and timing, not cost inefficiencies; full-year 42.5% midpoint remains consistent with 40%+ long-term targets.
• Net Revenue Retention: 108% is viewed as healthy; future growth driven by cross-sell within the large client cohort (currently averaging 5 products/click against 30+ module portfolio).
• AI Monetization: AI capabilities are monetized via new SKUs (e.g., recruitment), premium add-ons to existing modules, and outcome-based volume models.

Other Key Points:

• Implementation Backlog: Associated with opportunities >$100k grew >50% YoY and has a mid-30% two-year CAGR.
• Client Density: Large clients now use an average of 5 Waystar product modules.
• Strategic Wins: Displaced three incumbents via channel expansion in the ambulatory PT segment.
• Autonomous Claims: Early adopters of autonomous claim resubmission report significant manual work reduction and financial improvements.
• Conference Momentum: High interest from attendees at the "Waystar True North" conference regarding expanding platform usage.